Restructured Lombard targets profitability in 2004
This article was originally published in Clinica
Executive Summary
Lombard Medical CEO Steve Terry has laid down a new structure for the three-year-old Abingdon, UK medical technology company, and says profitability is achievable towards the end of 2004. Mr Terry, who joined Lombard in October 2002 prior to its relocation to the Oxford area, has now completed an overall strategy review, the result of which is that the company will focus on two core areas and three products in the immediate future.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.